<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational Trial
Lukas Kessler(German Cancer Research Center), Jens T. Siveke(German Cancer Research Center), Justin Ferdinandus(German Cancer Research Center), Anke Reinacher‐Schick(Ruhr University Bochum), Lale Umutlu(Essen University Hospital), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Wolfgang P. Fendler(Essen University Hospital), Marco Niedergethmann(University Medical Centre Mannheim), Céline Lugnier(Ruhr University Bochum), Nader Hirmas(Deutsches Konsortium für Translationale Krebsforschung), Rainer Hamacher(Technical University of Munich), Michael Nader(Deutsches Konsortium für Translationale Krebsforschung), Waldemar Uhl(Heidelberg University), Aleksandar Milošević(Essen University Hospital), Ken Herrmann(Klinikum rechts der Isar), David P. Witte(University Hospital Schleswig-Holstein), Benedikt M. Schaarschmidt(Essen University Hospital)
Cited by 34
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
IAP Guidelines for the Surgical Management of Acute Pancreatitis
|Pancreatology|2002|774
IAP Guidelines for the surgical management of acute pancreatitis
|Pancreatology|2002|531
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464